Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Medtronic
Covington
Fish and Richardson
Federal Trade Commission
Boehringer Ingelheim

Generated: September 17, 2019

DrugPatentWatch Database Preview

Patent: 7,459,601

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,459,601
Title:Human .alpha. synuclein expressing transgenic mice
Abstract: In methods for screening treatments for, and treatment of, neurodegenerative diseases, aggregation in neurons of NACP/.alpha.-synuclein is measured and expression of a non-amyloidogenic protein is stimulated in order to reduce the level aggregration. For purposes of screening agents for treatment of neurodegenerative disease, oxidative stress in the neuronal cells is stimulated by introducing a mixture of metal-ions and hydrogen peroxide. Examples of appropriate metals include iron, aluminum, and copper. After introduction of the agent under evaluation for stimulation of expression of non-amyloidogenic protein, the effectiveness is measured by testing for a decrease in the level of aggregation of NACP/.alpha.-synuclein. In an exemplary embodiment, the non-amyloidogenic protein is .beta.-synuclein. The aggregation of NACP/.alpha.-synuclein is dependent upon the concentration of metal ions in the neuronal cells. In addition, the presence of chelating agents appears to modulate the build-up of NACP/.alpha.-synuclein aggregates which are responsible for synaptic and neuronal dysfunction.
Inventor(s): Masliah; Eliezer (San Diego, CA), Hashimoto; Makoto (La Jolla, CA), Rockenstein; Edward (Chula Vista, CA), Mucke; Lennart (San Francisco, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Application Number:10/853,774
Patent Claims:see list of patent claims

Details for Patent 7,459,601

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04 ➤ Sign Up The Regents of the University of California (Oakland, CA) 2018-10-06 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04 ➤ Sign Up The Regents of the University of California (Oakland, CA) 2018-10-06 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04 ➤ Sign Up The Regents of the University of California (Oakland, CA) 2018-10-06 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
US Army
Boehringer Ingelheim
US Department of Justice
Daiichi Sankyo
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.